China A roundup of some of the latest news from Chinese pharma including CanSino’s Gates Foundation grant for polio vaccine R&D; Merck’s deal with Jiangsu Hengrui; the license agreement between GSK and Hansoh Pharma, and the China-based starteup Biotheus’ oncology partnership with BioNTech.   Chinese and Foreign Pharmaceutical, Medical Device Firms…

China After four years away, Brendan Shaw recently returned to China to attend the ChinaBio Innovation and Investment Conference in Suzhou. Although geopolitical tensions, the fallout from COVID-19, and local market challenges have dampened stakeholder optimism around China somewhat in the last few years, Shaw feels that the country still has…

China A roundup of some of the latest pharma news from China including Pfizer’s first Asia launch of Rimegepant migraine treatment in Hong Kong; Zhifei and GSK’s shingles vaccine deal, and the collaboration between the Chinese University of Hong Kong and the Olympus Corporation.   Chinese University of Hong Kong and…

China A decade on from its launch, the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) initiative has made some significant wins but remains some way from fulfilling the vision of a fully integrated internationally competitive bay area to rival that of its US west coast namesake.   Staggering Fundamentals Home to 87…

China Writing in the September 2023 edition of DIA’s Global Forum magazine, Shuting Li of Anhui Jimin Cancer Hospital and Xinfang Fan of Bayer Health Care Ltd. examine how Chinese clinical trials are increasingly focusing on patient engagement and patient centricity.   In recent years, with the Chinese government’s vigorous support…

China Ongoing geopolitical tensions between China and the West have led the G7 group of countries to warn of the threat of “economic coercion” from China and the US to scrutinise Chinese investment in its biotech sector more closely. Against this backdrop, and despite many of the leading lights in global…

China A roundup of some of the latest healthcare and pharma news from China including a crackdown on healthcare corruption; AstraZeneca’s cardiovascular mortality drug approval and mRNA manufacturing deal with CanSino; Tigermed’s new Hong Kong HQ; GenScript Biotech/T-Maximum Biotech CAR-T agreement, and the Chinese cabinet’s renewed efforts to encourage foreign biotech…

China Writing in the August edition of DIA’s Global Forum magazine, Wen Yin of the Pfizer China R&D Center and Wanhe Deng of GSK China Investment look back on four years of China’s marketing authorization holder (MAH)-based regulatory system, including the opportunities it presents, and some of the implementation challenges.  …

China At a time when the country’s economy has fallen into a slump with the currency sinking to its lowest level in 16 years, Chinese giant Fosun Pharma continues to agressively advance its activities in everything from pharmaceuticals to medical devices and diagnosis to healthcare services. Through its multiple subsidiaries, as…

China A roundup of some of the biggest recent stories coming out of China, including the commerce minister’s peace offering to international drug companies; CSPC Pharmaceutical Group’s partnership with Pfizer; Merck’s EUR 70 million manufacturing investment; the licensing agreement between Zhejiang Doer Biologics and BioNTech, and Moderna’s deal to develop and…

China A roundup of some of the most significant recent stories from the Chinese pharmaceutical industry, including a slate of international investment which seems to suggest that – despite ongoing political tensions – China remains an attractive market for multinational pharma.   AstraZeneca defies geopolitics to bet on China – Financial…

China Bridge Consulting examines the opportunities and challenges ahead for China’s mRNA vaccine industry in the post-COVID era. Having eschewed foreign-made mRNA products from Pfizer/BioNTech and Moderna during the peak of the pandemic in the hope of securing domestic alternatives, China and its sizeable biopharma industry now face a challenging path…